$-0.23
(Market cap
$12,507 Mln
Recently Viewed
Clear AllMarket cap
$12,507 Mln
Revenue (TTM)
$944 Mln
P/E Ratio
--
P/B Ratio
25.6
Div. Yield
0 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
$-381 Mln
ROE
-0.7 %
ROCE
-14.9 %
Industry P/E
--
EV/EBITDA
135.8
Debt to Equity
5.3
Book Value
$3
EPS
$-2.4
Face value
--
Shares outstanding
165,192,011
CFO
$522.87 Mln
EBITDA
$-838.91 Mln
Net Profit
$-804.33 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Ionis Pharmaceuticals (IONS)
| -5.7 | 5.1 | -8.8 | 157.0 | 26.4 | 11.9 | 5.6 |
|
BSE Sensex
| -8.3 | 4.2 | -5.6 | -2.4 | 9.2 | 10.1 | 11.6 |
|
S&P 100
| 1.3 | 10.1 | 2.5 | 37.6 | 22.9 | 13.3 | 14.2 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Ionis Pharmaceuticals (IONS)
| 126.3 | -30.7 | 33.9 | 24.1 | -46.2 | -6.4 | 11.7 |
|
S&P 100
| 18.7 | 29.0 | 30.8 | -22.1 | 27.6 | 19.3 | 29.5 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Ionis Pharmaceuticals (IONS)
|
74.6 | 12,506.7 | 944.0 | -381.0 | -31.6 | -70.7 | -- | 25.6 |
| 312.6 | 41,317.3 | 3,713.9 | 313.8 | 11.2 | 73.3 | 133.5 | 52.4 | |
| 143.1 | 31,186.3 | 606.4 | -1,276.8 | -196.7 | -249.3 | -- | 42.2 | |
| 161.3 | 29,945.3 | 16,310.0 | 1,360.0 | 14.2 | 21.6 | 21.9 | 4.4 | |
| 54.7 | 21,304.7 | 1,944.0 | -2,822.0 | -142.4 | -28.9 | -- | 2.5 | |
| 131.4 | 13,402.6 | 2,860.5 | 478.6 | 24.1 | 16.4 | 28.5 | 4.1 | |
| 754.6 | 79,350.1 | 14,342.9 | 4,504.9 | 36.8 | 14.9 | 18.1 | 2.5 | |
| 23.3 | 19,500.6 | 0.0 | -1,079.6 | -- | -206.1 | -- | 29.6 | |
| 571.8 | 25,787.3 | 3,182.7 | 1,334.7 | 54.1 | 19.7 | 21.1 | 3.6 | |
| 437.8 | 112,223.5 | 12,074.6 | 3,953.2 | 38.4 | 22.5 | 28.8 | 5.9 |
Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute... pancreatitis; DAWNZERA for prophylaxis to prevent attacks of hereditary angioedema in adults; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 which is in Phase 3 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California. Read more
Founder, CEO & Director
Dr. Brett P. Monia Ph.D.
Founder, CEO & Director
Dr. Brett P. Monia Ph.D.
Headquarters
Carlsbad, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Ionis Pharmaceuticals Inc (IONS) is $74.60 (NASDAQ) as of 23-Apr-2026 10:38 EDT. Ionis Pharmaceuticals Inc (IONS) has given a return of 26.41% in the last 3 years.
Since, TTM earnings of Ionis Pharmaceuticals Inc (IONS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-33.64
|
26.20
|
|
2024
|
-12.17
|
9.39
|
|
2023
|
-20.10
|
19.04
|
|
2022
|
-19.88
|
9.36
|
|
2021
|
-170.26
|
6.31
|
The 52-week high and low of Ionis Pharmaceuticals Inc (IONS) are Rs 86.74 and Rs 28.79 as of 23-Apr-2026.
Ionis Pharmaceuticals Inc (IONS) has a market capitalisation of $ 12,507 Mln as on 17-Apr-2026. As per SEBI classification, it is a Large Cap company.
Before investing in Ionis Pharmaceuticals Inc (IONS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.